BD reported 8.1% growth in base revenues for the first quarter of the fiscal year 2022. Credit: SKreutz / commons.wikimedia.org.

Becton, Dickinson and Company (BD) has reported $5bn of revenue for the first quarter (Q1) of the fiscal year 2022, representing a decline of 6% on reported and 5.9% on currency-neutral basis due to a fall in Covid-only testing revenues across the world.

In base revenues, the company reported 8.1% growth as reported and 8.3% on currency-neutral basis.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

BD’s Medical segment reported growth in revenue, which was driven by strong performance in the Medication Delivery Solutions (MDS) and Pharmaceutical Systems (PS) units.

The Medical segment’s revenue for the quarter stood at $2.39bn, representing a 6% rise when compared to $2.26bn in 2020.

Recently, the company received 510(k) clearance for BD Kiestra IdentifA from the US Food and Drug Administration (FDA). Using smart connected robotics, the device automates the preparation of microbiology bacterial identification testing.

See Also:

It also announced new distribution and retail partners for its BD Veritor At-Home COVID-19 Test.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Last December, BD concluded the purchase of Scanwell Health in order to expand and scale digital at-home medical testing.

The company also marked its entry point into the treatment of chronic venous insufficiency with the acquisition of Venclose.

Additionally, BD completed the acquisition of self-adhesive surgical sealant films developer Tissuemed and flow cytometry solutions provider Cytognos.

BD chairman, CEO and president Tom Polen said: “We continue to advance our innovation pipeline and tuck-in M&A strategy, strengthening our leadership position in our durable core and adding transformative solutions to our portfolio.

“As we look forward, we are confident in our ability to deliver on our commitments and are well-positioned to create long-term growth and value for all our stakeholders.”